These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31382295)

  • 1. Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study.
    Kaneko Y; Nunokawa T; Taniguchi Y; Yamaguchi Y; Gono T; Masui K; Kawakami A; Kawaguchi Y; Sato S; Kuwana M;
    Rheumatology (Oxford); 2020 Jan; 59(1):112-119. PubMed ID: 31382295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
    Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases.
    Li S; Sun Y; Shao C; Huang H; Wang Q; Xu K; Zhang X; Liu P; Zeng X; Xu Z
    Rheumatology (Oxford); 2021 Mar; 60(3):1195-1204. PubMed ID: 32894294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
    Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
    Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients.
    Sato S; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Tamura M; Ikeda K; Nunokawa T; Tanino Y; Asakawa K; Kaneko Y; Gono T; Ukichi T; Kaieda S; Naniwa T; Kuwana M;
    Rheumatology (Oxford); 2018 Jul; 57(7):1212-1221. PubMed ID: 29596687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk factors for cancer-associated myositis: A large-scale multicenter cohort study.
    Li Y; Jia X; Sun X; Shi L; Lin F; Gan Y; Zhang X; Gao X; Miao M; Hong D; Li Y; He J
    Int J Rheum Dis; 2021 Feb; 24(2):268-273. PubMed ID: 33369084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
    Gono T; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Ikeda K; Kirino Y; Sugiyama Y; Tanino Y; Nunokawa T; Kaneko Y; Sato S; Asakawa K; Ukichi T; Kaieda S; Naniwa T; Okano Y; Kuwana M;
    Arthritis Rheumatol; 2021 Apr; 73(4):677-686. PubMed ID: 33118321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
    Yoshifuji H; Fujii T; Kobayashi S; Imura Y; Fujita Y; Kawabata D; Usui T; Tanaka M; Nagai S; Umehara H; Mimori T
    Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
    Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
    Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
    Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
    J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease.
    Wang Y; Chen S; Lin J; Xie X; Hu S; Lin Q; Zheng K; Du G; Huang X; Zhang G; Gargani L; Matucci-Cerinic M; Furst DE
    Rheumatology (Oxford); 2020 Aug; 59(8):2024-2029. PubMed ID: 31794028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
    Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
    Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
    J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis.
    Friedman AW; Targoff IN; Arnett FC
    Semin Arthritis Rheum; 1996 Aug; 26(1):459-67. PubMed ID: 8870113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.